东富龙2025上半年营收24.29亿元 国际市场业务取得重大突破

Core Insights - The company reported a revenue of 2.429 billion yuan for the first half of 2025, representing a year-on-year growth of 6.01% [1] - The net profit attributable to shareholders decreased by 59.71% to 45.9195 million yuan [1] - The net cash flow from operating activities increased by 43.96% to 276 million yuan [1] International Market Performance - The international business achieved significant breakthroughs, with revenue of 805 million yuan, accounting for 33.14% of total revenue, and a year-on-year growth of 63.25% [1] - The gross margin for international business was 48.03%, an increase of 1.84% compared to the previous year [1] Food Equipment Sector - The food equipment sector secured large international orders, generating revenue of 222 million yuan, which is a 73.77% increase year-on-year [1] - The gross margin for this sector increased by 5.45% compared to the previous year [1] Strategic Development - The company adheres to a development strategy focused on "systematic, international, and intelligent" growth, aiming to enhance product competitiveness and overall functionality [1] - Efforts are being made to strengthen overseas marketing and increase brand recognition to enter more international pharmaceutical supplier lists [1] Technological Advancements - The company launched the first domestic dual-chamber freeze-dried preparation production line, achieving milestone progress in process breakthroughs and core equipment localization [2] - This technology significantly optimizes patient treatment experiences and enhances medication safety and compliance [2] Profit Distribution - The company announced a mid-year profit distribution plan, proposing a cash dividend of 0.30 yuan per 10 shares, totaling 22.8254 million yuan [2] Company Overview - The company is a comprehensive pharmaceutical equipment service provider, serving over 3,000 global pharmaceutical enterprises in more than 50 countries [2] - It is recognized as a leading player in the domestic pharmaceutical equipment industry and a representative of domestic alternatives to imported pharmaceutical equipment [2]